kinezodianone R hydrochloride (T4090)
/ Thea Laboratories
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
October 02, 2024
Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients with Open-angle Glaucoma or Ocular Hypertension
(clinicaltrials.gov)
- P2 | N=126 | Active, not recruiting | Sponsor: Laboratoires Thea | Recruiting ➔ Active, not recruiting
Enrollment closed • Cardiovascular • Glaucoma • Ophthalmology
August 29, 2024
Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
(clinicaltrials.gov)
- P2 | N=126 | Recruiting | Sponsor: Laboratoires Thea | Not yet recruiting ➔ Recruiting
Enrollment open • Cardiovascular • Glaucoma • Ophthalmology
May 01, 2024
Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
(clinicaltrials.gov)
- P2 | N=126 | Not yet recruiting | Sponsor: Laboratoires Thea
New P2 trial • Cardiovascular • Glaucoma • Ophthalmology
February 07, 2024
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
(clinicaltrials.gov)
- P1/2 | N=120 | Active, not recruiting | Sponsor: Laboratoires Thea | Recruiting ➔ Active, not recruiting
Enrollment closed • Cardiovascular • Glaucoma • Ophthalmology
July 19, 2022
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
(clinicaltrials.gov)
- P1/2 | N=120 | Recruiting | Sponsor: Laboratoires Thea | Not yet recruiting ➔ Recruiting
Enrollment open • Cardiovascular • Glaucoma • Ophthalmology
May 25, 2022
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
(clinicaltrials.gov)
- P1/2 | N=120 | Not yet recruiting | Sponsor: Laboratoires Thea
New P1/2 trial • Glaucoma • Ophthalmology
1 to 6
Of
6
Go to page
1